Log In
Print
BCIQ
Print
Print this Print this
 

PUR0200

  Manage Alerts
Collapse Summary General Information
Company Pulmatrix Inc.
DescriptionInhaled dry powder formulation of a long-acting muscarinic receptor antagonist enabled by a non-lactose approach using Pulmatrix's iSPERSE delivery technology
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat moderate chronic obstructive pulmonary disease (COPD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today